Multiplier AI IPO Details
Multiplier AI IPO Summary
Multiplier AI IPO DRHP (Draft Red Herring Prospectus) has been Filed with Exchange.
Pre-issue shareholding stands at 84,24,885, which will increase to 1,19,24,885 post-issue.
Multiplier AI IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
The Lead Managers for Multiplier AI IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Swastika Investmart Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Multiplier AI Limited DRHP.
Multiplier AI IPO Details
Multiplier AI IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| To be announced | |||
Multiplier AI IPO Reservation
Promoter Holding
Documents
Multiplier AI IPO Valuations
Multiplier AI Financial Information
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 17.16 | 13.47 | 11.85 | 7.95 |
| Total Income | 7.02 | 11.65 | 15.75 | 10.3 |
| Profit After Tax | 3.24 | 4.1 | 1.33 | 0.63 |
| Net Worth | 13.02 | 9.79 | 5.68 | 4.35 |
| Reserves and Surplus | 4.6 | 9.38 | 5.28 | 3.95 |
| Amount in ₹ Crore | ||||
About Multiplier AI IPO
Incorporated in July 2011, Multipliers AI Limited provides AI solutions to pharmaceutical companies through advanced analytics, predictive modeling, and marketing.
The company offers AI solutions, including Gen AI Doctor Data Platform, Hyper Personalized Content, DPDP Compliant HCP Marketing, GPT & LLM Tools for Pharmaceutical companies, and platforms for patient intelligence, doctor referrals, and attracting new patients, enabling clients to adapt to market changes and seize opportunities quickly.
The company utilizes advanced AI algorithms to generate personalized content, analyze patient data, and identify key physician influencers.
The company's clientele spans global pharmaceutical giants, healthcare providers, and specialized firms.
The company offers the following services:
- Data insights:Extracting valuable insights from complex healthcare datasets to inform marketing strategies.
- Physician influencer marketing:Targeting and engaging influential doctors to promote products and services.
- Content creation:Generating tailored marketing materials using generative AI.
As of February 2025, the company has 59 clients in total.
As of December 31, 2024, the company had 84 dedicated professionals, with no contracted employees on its payroll.
Competitive Strength
- Converting non-prescribers expands the pharmaceutical market.
- Boost prescription sales by optimizing engagement and targeting.
- Building networks of physician digital influencers.
- Create bot engagement programs for physicians to enable efficient interactions.
Strength Of Multiplier AI IPO
Risk Of Multiplier AI IPO
Objectives Multiplier AI IPO
- Strategic Growth in India and US: Strengthening Workforce, IT investments and Leasing of Co-Working Spaces;
- Establishment of AI R&D Center (AI Server & Software);
- General Corporate Purposes.
Company Contact Details
Multiplier AI Ltd.
H. No. 1-98/9/3/51, Plot No.53, Survey No. 70 & 71
RS Silicon Park, 5th Floor, Serilingampally
Madhapur Shaikpet,-
Hyderabad, Telangana, 500081
Phone: 9154045585
Email: cs@multipliersolutions.com
Website: https://multiplierai.co/
Registrar Contact Details
Market Maker
Multiplier AI FAQs
The Multiplier AI IPO is a SME public issue comprising 0 equity shares with a face value of ₹10 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at TBA.
Quick Links
Comments
